Annual Accounts Receivable
$22.45 M
+$9.92 M+79.19%
December 31, 2023
Summary
- As of February 7, 2025, YMAB annual accounts receivable is $22.45 million, with the most recent change of +$9.92 million (+79.19%) on December 31, 2023.
- During the last 3 years, YMAB annual accounts receivable has risen by +$22.45 million (+100.00%).
- YMAB annual accounts receivable is now at all-time high.
Performance
YMAB Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$19.92 M
-$2.27 M-10.25%
September 30, 2024
Summary
- As of February 7, 2025, YMAB quarterly accounts receivable is $19.92 million, with the most recent change of -$2.27 million (-10.25%) on September 30, 2024.
- Over the past year, YMAB quarterly accounts receivable has dropped by -$2.54 million (-11.30%).
- YMAB quarterly accounts receivable is now -11.30% below its all-time high of $22.45 million, reached on December 31, 2023.
Performance
YMAB Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
YMAB Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +79.2% | -11.3% |
| 3 y3 years | +100.0% | +58.9% |
| 5 y5 years | - | +58.9% |
YMAB Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +191.2% | -11.3% | +176.3% |
| 5 y | 5-year | at high | -100.0% | -11.3% | -100.0% |
| alltime | all time | at high | -100.0% | -11.3% | -100.0% |
Y-mAbs Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $19.92 M(-10.3%) |
| Jun 2024 | - | $22.19 M(+7.8%) |
| Mar 2024 | - | $20.59 M(-8.3%) |
| Dec 2023 | $22.45 M(+79.2%) | $22.45 M(+19.0%) |
| Sep 2023 | - | $18.87 M(-1.3%) |
| Jun 2023 | - | $19.12 M(+2.2%) |
| Mar 2023 | - | $18.70 M(+49.2%) |
| Dec 2022 | $12.53 M | $12.53 M(+35.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $9.25 M(+28.3%) |
| Jun 2022 | - | $7.21 M(-22.7%) |
| Mar 2022 | - | $9.32 M(+20.9%) |
| Dec 2021 | $7.71 M(>+9900.0%) | $7.71 M(+6.2%) |
| Sep 2021 | - | $7.26 M(-14.7%) |
| Jun 2021 | - | $8.52 M(+42.0%) |
| Mar 2021 | - | $6.00 M(>+9900.0%) |
| Dec 2020 | $0.00 | $0.00 |
FAQ
- What is Y-mAbs Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual accounts receivable year-on-year change?
- What is Y-mAbs Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly accounts receivable year-on-year change?
What is Y-mAbs Therapeutics annual accounts receivable?
The current annual accounts receivable of YMAB is $22.45 M
What is the all time high annual accounts receivable for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual accounts receivable is $22.45 M
What is Y-mAbs Therapeutics annual accounts receivable year-on-year change?
Over the past year, YMAB annual accounts receivable has changed by +$9.92 M (+79.19%)
What is Y-mAbs Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of YMAB is $19.92 M
What is the all time high quarterly accounts receivable for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly accounts receivable is $22.45 M
What is Y-mAbs Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, YMAB quarterly accounts receivable has changed by -$2.54 M (-11.30%)